Intelligencia AI Topics of Most Interest Question Title * 1. What type of content would you like us to focus on more in 2026? Predictive analytics on clinical success and failure (PTRS-driven insights on which programs, mechanisms, or modalities are most likely to succeed—and why.) Pre-conference and pre-data-readout analyses (Forward-looking assessments ahead of ASCO, ESMO, ASH, AHA, ADA, etc.) Deep dives into therapeutic area inflection points (Where the science, regulation, and competitive landscape are structurally shifting (e.g., CAR-T in solid tumors, GLP-1 saturation, IL-17/23 replacing TNF). Late-stage development risk and Phase 3 bottlenecks (Why programs fail late, how trial design choices influence outcomes, and what historically works.) Mechanism- and modality-level benchmarking (How ADCs, bispecifics, CAR-T, small molecules, biologics, and emerging platforms truly perform across phases and indications.) Regulatory and endpoint strategy insights (What regulators are actually accepting (and rejecting): MRD, surrogate endpoints, accelerated approvals, safety signals.) Competitive landscape and white-space analyses (Where pipelines are overcrowded, where momentum is peaking, and where genuine opportunity remains.) Disease-specific spotlights tied to awareness months (Data-driven perspectives on current development reality, not advocacy-level summaries.) Trial design strategy: monotherapy vs combination, line of therapy, patient selection (Evidence-based guidance on how design choices impact success probability.) AI in drug development: what works vs what’s hype (Practical applications of AI in clinical strategy, portfolio decisions, and risk reduction.) Question Title * 2. Where are you based? Europe United States Asia Other Question Title * 3. Which function do you work in? Clinical Development / R&D Portfolio Strategy & Management Business Development & Licensing / Search & Evaluation Commercial / New Product Planning Competitive Intelligence Data Science Other Done